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ABSTRACT
In a phase I/II study, the combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) was investi-
gated as graft-versus-host disease (GVHD) prophylaxis after myeloablative conditioning and hematopoietic
cell transplantation from an HLA-matched sibling donor. In phase I, 3 groups, each with 10 or 11 patients,
received MMF (15 mg/kg) from day 0 to day 27 at decreasing dose intervals of every 12, 8, and 6 hours to
determine a safe and effective total daily dose. At the 45 mg/kg/d dosage level, 4 of 11 patients developed only
grade II GVHD, and a concentration at steady state of mycophenolic acid (the active moiety of MMF)
consistent with a therapeutic range described for solid-organ transplantation was achieved. There was a
suggestion of increased toxicity without improved efficacy at the 60 mg/kg/d dosage level. Accordingly, the 45
mg/kg/d dosage was therefore selected for phase II, and another 15 patients were added to this group from the
phase I study (n  26). The concentrations at steady state for this dosage at days 0, 6, 13, 20, and 27 were 2.73,
3.02, 3.20, 2.62, and 2.64 g/mL, respectively. No toxicities were attributed to MMF at this dose. The median
time to engraftment after hematopoietic cell transplantation was 15 days (range, 10-20 days). The incidence of
acute GVHDwas 62%, which was comparable to a group of historical controls receiving CSP and methotrexate
(MTX) for GVHD prophylaxis. Although a significant improvement in the prevention of GVHD was not
suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in
which MTX is contraindicated.
© 2005 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Acute graft-versus-host disease (GVHD) contrib-
tes signiﬁcantly to the morbidity and mortality asso-
iated with allogeneic hematopoietic cell transplanta-
ion (HCT) and limits its broader application to
atients with nonmalignant and malignant diseases.
he combination of cyclosporine (CSP) and metho- g
B&MTrexate (MTX) is more effective than either agent
lone for the prevention of acute GVHD [1,2]. Later
tudies documented that tacrolimus in combination
ith MTX was more effective than CSP and MTX for
VHD prophylaxis but that other outcomes, includ-
ng overall survival, were no different between the 2
roups [3,4]. In many HCT programs, the combina-
495
t
a
p
n
d
m
G
t
M
e
M
r
i
d
(
h
a
p
P
i
o
e
P
m
C
e
d
m
v
m
b
a
n
v
i
o
c
p
p
e
h
t
m
d
a
c
u
l
c
s
i
p
I
o
r
P
P
p
H
S
N
c
m
t
P
s
a
i
r
t
v
t
c
(
b
c
m
t
c
w
r
f
t
i
v
i
s
a
h
p
S
I
t
H
s
m
t
s
p
a
1
t
s
1
i
i
m
R. A. Nash et al.
4ion of a calcineurin inhibitor with MTX has been
dopted as the standard of practice for GVHD pro-
hylaxis after allogeneic HCT. Although the combi-
ation of these immunosuppressive agents has re-
uced the incidence of acute GVHD, newer agents
ay further reduce the incidence or severity of acute
VHD and may avoid the toxicities associated with
he previously used regimens. After allogeneic HCT,
TX is associated with delayed engraftment and an
xacerbation of both oral and gastrointestinal toxicity.
oreover, the use of MTX is limited in patients with
enal dysfunction or with signiﬁcant “third spacing”
ncluding ascites or a pleural effusion.
Mycophenolate mofetil (MMF) is an ester pro-
rug of the immunosuppressant mycophenolic acid
MPA). After oral administration, MMF is rapidly
ydrolyzed to MPA, which is a selective, reversible,
nd noncompetitive inhibitor of inosine monophos-
hate dehydrogenase (IMPDH). Inhibition of IM-
DH blocks the de novo pathway of purine synthesis
n T and B lymphocytes [5]. Phase III clinical studies
f kidney transplantation have shown that MMF is
ffective in the prevention of graft rejection [6-8].
reclinical studies of allogeneic HCT in a canine
odel have shown that MMF in combination with
SP has activity in preventing GVHD [9]. After my-
loablative transplantation of marrow from unrelated
og leukocyte antigen-mismatched donors in a canine
odel of HCT, MMF synergized with CSP to pre-
ent GVHD and improve survival. In the canine
odel of nonmyeloablative transplantation, the com-
ination of CSP and MMF prevented graft rejection,
nd this combination is now commonly used after
onmyeloablative conditioning regimens for the pre-
ention of graft rejection and GVHD [10-12]. There
s a paucity of information regarding the effectiveness
f MMF in preventing GVHD after myeloablative
onditioning and allogeneic HCT. In a study of 14
atients receiving oral MMF with CSP, the maximum
lasma concentrations (Cmax) of MPA were lower than
xpected on the basis of pharmacokinetic data from
ealthy volunteers and solid-organ transplant patients,
hus suggesting that an intravenous (IV) formulation
ay be beneﬁcial to HCT patients [13]. The inci-
ence of GVHD was not decreased relative to CSP
nd MTX [13]. Also of interest was that plasma MPA
oncentrations were also low when oral MMF was
sed for treatment of acute GVHD compared with
evels achieved when it was used for the treatment of
hronic GVHD [14]. On the basis of the demon-
trated effectiveness of MMF for GVHD prevention
n the preclinical study and the observation that MPA
lasma levels were low after allogeneic HCT, a phase
/II study was conducted to evaluate the combination
f CSP and MMF after a myeloablative conditioning
egimen to identify a safe and effective dose of MMF. p
96ATIENTS AND METHODS
atients
Between November 1999 and October 2002, 46
articipants were enrolled in the study at the Fred
utchinson Cancer Research Center (n  29),
tanford University (n  12), and City of Hope
ational Medical Center (n  5). Data collection was
ompleted and analyzed for safety and efﬁcacy at 3
onths. After 3 months, data collection was limited to
he status of chronic GVHD, relapse, and survival.
atients 65 years of age or younger were eligible for
tudy participation if they were scheduled to receive
n unmodiﬁed hematopoietic cell graft from an HLA-
dentical sibling after a myeloablative conditioning
egimen for advanced hematologic malignancies, mul-
iple myeloma, or myelodysplastic syndrome. Ad-
anced hematologic malignancies were deﬁned for
his study as acute myeloid leukemia or acute lympho-
ytic leukemia beyond a ﬁrst complete remission
CR); secondary acute myeloid leukemia in ﬁrst CR or
eyond; chronic myelogenous leukemia in second
hronic phase, accelerated phase, or blast crisis; and
alignant lymphoma greater than second CR. Pa-
ients were excluded from the study if the estimated
reatinine clearance was less than 60 mL/min or there
as an abnormal liver function with total serum bili-
ubin greater than 1.5 times or aspartate aminotrans-
erase/alanine aminotransferase greater than 2 times
he upper limit of normal. Patients were also excluded
f serology was positive for human immunodeﬁciency
irus or if there were uncontrolled infections. The
nstitutional review board at each center approved the
tudy, and patients were registered on the study only
fter providing signed consent to conﬁrm that they
ad been fully informed of the investigational pur-
oses of the study.
tudy Design
The study was an open-label multicenter phase
/II study of the combination of CSP and MMF for
he prevention of acute GVHD after HCT from
LA-identical siblings. In the phase I part of the
tudy, the MMF dose was escalated to determine the
aximal effective but safe dose. Because the elimina-
ion half-life of the active metabolite MPA seemed
horter in HCT patients relative to solid-organ trans-
lant patients, escalation of the total daily dose was
chieved by decreasing the dosing interval from every
2 hours (group A) to every 8 hours (group B) and
hen to every 6 hours (group C). Pharmacokinetic
tudies of MPA were performed in all patients. At least
0 patients were accrued to each dose level, and an
nterim analysis was planned when the last patient
ncluded in that group had been followed up for 3
onths. When an optimal dose was identiﬁed, the
hase II part of the study was started, and 15 patients
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CSP and MMF for Acute GVHD Prevention after Myeloablative HCT
Bere added to the group of patients who had received
he optimal dose (group D). The primary objective of
he phase II part of the study was to estimate the
fﬁcacy of CSP in combination with the optimal dose
f MMF in preventing grade II to IV acute GVHD.
ecent data from our institutions suggested that for a
opulation of patients comparable to those included in
his study with advanced hematologic malignancies
nd who received peripheral blood stem cell grafts but
SP and MTX for GVHD prophylaxis, the incidence
f acute GVHD was between 70% and 80% [15-17].
n the basis of the analysis of these historical controls,
t was determined that the combination of CSP and
MF would be considered successful in this study if
he true rate of acute GVHD were less than 60%. If
2 or fewer of 25 patients developed acute GVHD,
here would be an 80% conﬁdence limit that the true
ate of acute GVHD was less than 60% and of poten-
ial interest for a phase III study.
LA Typing
All donors of the hematopoietic cell grafts were
ull siblings who were matched serologically or by
olecular typing for HLA-A, -B, and -C and allele-
atched for HLA-DRB1 and -DQB1.
ransplantation Procedure and Supportive Care
Preparative regimens were assigned according to
he treatment protocols at the investigational sites. All
atients received a myeloablative conditioning regi-
en that included either total body irradiation or
usulfan. Intrathecal therapy with MTX was given if
edically indicated. An unmodiﬁed hematopoietic
ell graft was infused on day 0. All patients were
reated with a preemptive therapy strategy for cyto-
egalovirus (CMV), preventative therapy for herpes
implex virus and varicella-zoster virus, and antifungal
rophylaxis according to institutional protocols.
Both the IV and the oral doses of MMF were
alculated by using adjusted ideal body weight. In
hase I, the total daily dose of MMF was increased by
sing 3 different dosing schedules. The 3 administra-
ion schedules were 15 mg/kg every 12 hours (group
), every 8 hours (group B), and every 6 hours (group
) from day 0 to day 27. The ﬁrst MMF dose on day
was administered at least 2 hours after the end of the
nfusion of the hematopoietic cell graft. All patients
eceived the IV formulation of MMF as a 2-hour
nfusion in 5% dextrose until at least day 14 after
CT. When patients had recovered from the regi-
en-related gastroenteritis and were capable of re-
eiving the oral formulation of MMF, they were con-
erted at an oral/IV ratio of 1:1. The oral formulation
f MMF was available only in 250-mg capsules, so the
rescribed dose was rounded to the nearest possible
ose. If in the clinical judgment of the investigator an t
B&MTbserved toxicity was related to MMF, the dose was
djusted. If signiﬁcant gastrointestinal toxicity oc-
urred, then the MMF dose was reduced by 50%, and
f there was no improvement in 48 to 72 hours, then
MF was stopped. If renal insufﬁciency occurred (ie,
decrease in the estimated creatinine clearance to
5-60 mL/min), then the dose of MMF was reduced
y 25%. If the estimated creatinine clearance was less
han 25 mL/min, then the dose of MMF was reduced
y 50%. No adjustment of the MMF dose was re-
uired for liver dysfunction.
All patients received CSP (3 mg/kg/d IV initially
nd then converted to the oral formulation when tol-
rated) from day 1 until day 50. Dosing was based
n adjusted ideal body weight. CSP whole blood levels
ere monitored and adjusted to maintain therapeutic
evels per site-speciﬁc standard practice. If GVHD
as absent, CSP was then tapered by 5% per week
rom day 50 until day 180, when the drug was discon-
inued.
ngraftment
Engraftment was deﬁned as occurring on the ﬁrst
f 3 successive days after HCT with neutrophil counts
.5  109/L or higher. Platelet recovery was deﬁned
s the ﬁrst of 7 successive days during which platelet
ounts were greater than 20 000/L and no platelet
ransfusions were administered.
dverse Events
Toxicities were graded according to the National
ancer Institute Common Toxicity Criteria for de-
criptive purposes. Most adverse events to day 35 after
llogeneic HCT are related to the myeloablative con-
itioning regimen, GVHD, or infections. Because he-
atopoietic toxicity had been observed in other stud-
es of MMF, a delay in the recovery of neutrophils to
00/L to more than 28 days after marrow transplan-
ation or more than 24 days after peripheral blood
tem cell transplantation was also considered to be a
ose-limiting toxicity. Diarrhea volumes were re-
orded from day 0 to day 21 and were compared
etween groups at the different dose levels of MMF.
ucositis was clinically evaluated and scored for the
hase II patients only. Oral examinations to assess
ucositis severity were performed on a set schedule
days 0, 4, 7, 11, 14, 18, and 21  1 day), and the
coring of mucositis was accomplished by using the
ral mucositis index [18]. CMV reactivation and in-
ections after HCT were reported to day 100. Primary
auses of death were categorized according to Na-
ional Marrow Donor Program criteria.
ssessment and Treatment of GVHD
An overall grade of acute GVHD was assigned by
he site investigator at each institution according to
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4linical assessment by using modiﬁed Seattle criteria
19,20]. Biopsy samples were obtained when indicated
o corroborate the clinical diagnosis of GVHD. Pa-
ients were censored for the evaluation of acute
VHD at the time of relapse or death. Treatment of
rade II to IV acute or chronic GVHD was deter-
ined by the investigational site; however, all primary
ystemic therapy was with corticosteroids. A patient was
valuable for chronic GVHD if engraftment occurred
nd the patient survived without relapse for 75 days after
CT. Assessments of chronic GVHD were made ac-
ording to previously described criteria [21,22].
harmacokinetic Analysis
Blood samples for MPA pharmacokinetics were
ollected in ethylenediaminetetraacetic acid tubes on
ays 0, 7, 14, 21, and 27 after HCT. The pharmaco-
inetic blood samples were obtained at 0, 1, 2, 4, 6, 8,
nd 10 hours in group A (administration every 12
ours); at 0, 1, 2, 4, and 8 hours in group B (admin-
stration every 8 hours); and at 0, 1, 2, 4, and 6 hours
n those receiving MMF (administration every 6
ours). Blood was collected (2 mL) in Vacutainers
Becton-Dickinson, Franklin Lakes, NJ) containing
odium ethylenediaminetetraacetic acid and centri-
uged at 4°C, and the plasma was stored at 70°C.
otal MPA plasma levels were quantiﬁed by reverse-
hase high-performance liquid chromatography with
V detection (adapted from Tsina et al. [23]) [24].
he dynamic range was 0.2 to 30 g/mL, and the
nterday coefﬁcient of variation was less than 10%.
he unbound fraction of MPA was separated from the
rotein-bound MPA through equilibrium dialysis and
easured as described previously. The total MPA and
he fraction of MPA bound to plasma protein (bMPA)
as quantitated, and the percentage of unbound drug
as calculated as 100  (1  bMPA). Thus, the
nbound fraction is the percentage of MPA unbound
ivided by (% unbound  % bound).
After quantitation, noncompartmental analysis of
oncentration-time data was conducted to estimate
he area under the plasma concentration-time curve
AUC). Concentration at steady state (Css) was calcu-
ated by dividing the AUC by the dosing interval; for
xample, AUC was divided by 12 hours in the twice-
aily MMF group to compare the groups of patients
25]. Pharmacokinetic data were excluded from the
nalysis if there were fewer than 4 time points avail-
ble, if the ﬁrst concentration-time point was obtained
onger than 2.5 hours after administration, or if no
amples were obtained for longer than 4 hours on a
articular day.
Elimination half-life was not estimated on those
ays if fewer than 3 concentration-time points were
btained after the Cmax, if the last 2 to 4 concentra-
ion-time points were of similar concentration (ie, s
98ithin 10%), or if there was evidence of a secondary
eak. Bioavailability was calculated by dividing the
UC after oral administration by the AUC after IV
dministration. The bioavailability could not be eval-
ated in patients who had pharmacokinetic sampling
erformed only after IV administration (n 17) or in
hose whose MPA AUC could not be estimated after
V administration (n 3); thus, 26 patients were
valuable for bioavailability.
tatistical Analysis
The primary efﬁcacy outcome for this study was
he occurrence of grade II to IV acute GVHD. Sec-
ndary efﬁcacy outcomes included the occurrence of
evere (grade III to IV) acute GVHD, chronic
VHD, relapse, or death. Survival and disease-free
urvival curves were estimated by the Kaplan-Meier
ethod. A time-dependent Cox regression analysis
as used to relate the total and unbound Css of MPA
o the occurrence of GVHD. Comparisons of diarrhea
olume between dose groups were made by using
nalysis of variance on ranked values of the mean
olume, calculated from days 1 to 21.
ESULTS
atient and Transplant Characteristics
Forty-six patients were enrolled in the study: 31 in
he phase I part of the study at 3 different dose levels and
5 in the phase II part of the study. Demographics and
ransplant characteristics of the study population are
able 1. Patient Characteristics (n  46)
Variable Data
ge, y, median (range) 49 (18-64)
ale gender (n) 29
isease type and stage (n)
AML (>1CR) 20
Biphenotypic leukemia 2
ALL (>1CR) 5
CML-BC 1
MDS 8
NHL 10
onditioning regimen (n)
CY/TBI 21
Bu/CY 12
CY/V/TBI 8
Other 5
tem cell source (n)
PBSC 45
Marrow 1
LL indicates acute lymphocytic leukemia; AML, acute myeloge-
nous leukemia; Bu, busulfan; CML-BC, chronic myelogenous
leukemia in blast crisis; CY, cyclophosphamide; MDS, myelo-
dysplastic syndrome; NHL, non-Hodgkin lymphoma; PBSC,
peripheral blood stem cells; TBI, total body irradiation; V,
etoposide; 1CR, ﬁrst complete remission.ummarized in Table 1. The median age of the study
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Bopulation was 49 years (range, 18-64 years). All patients
ut 1 received peripheral blood stem cell grafts.
harmacokinetics
The results of the pharmacokinetic studies for AUC,
ss, clearance, Cmax, Tmax, Ctrough, and t1/2 are reported
n Tables 2 and 3. There was no apparent difference in
UC as the dosing interval was decreased; however, the
ss increased consistent with the increased total daily
ose. The median MPA clearance was 0.66 L/h-kg
range, 0.62-3.6 L/h-kg), and it did not change from days
to 27. The interdose (ie, intrapatient) variability in
PA clearance after IV or oral administration could be
valuated in 36 patients, 17 (47%) of whom had a greater
han 30% change in their clearance of MPA over days 0
able 2. Total MPA Pharmacokinetics after IV Administration
Variable n
MPA AUC
(gh/mL)
MPA Css
(g/mL)
MPA
Cleara
(L/h-k
very-12-h administration
Day 0 9 23.1 1.92 0.63
(14.1-30.4) (1.17-2.53) (0.49-1.
Day 7 9 14.3 1.19 1.04
(13.1-27.7) (1.09-2.31) (0.54-1.
Day 14 9 34.5 2.88 0.41
(11.3-73.4) (0.94-6.12) (0.2-1.3
very-8-h administration
Day 0 25 21.9 2.73 0.69
(4.17-63.7) (0.52-7.97) (0.24-3.
Day 7 24 24.1 3.02 0.6
(6.24-47.7) (0.78-5.96) (0.31-2.
Day 14 23 25.6 3.20 0.58
(11.7-53.5) (1.46-6.69) (0.28-1.
very-6-h administration
Day 0 10 16.4 2.73 0.92
(9.15-29.5) (1.52-4.91) (0.52-1.
Day 7 9 19.49 3.25 0.76
(11.5-35.3) (1.91-5.86) (0.40-1.
Day 14 7 29 4.84 0.54
(13.7-35.1) (2.29-5.85) (0.43-1.
able 3. Total MPA Pharmacokinetics after Oral Administration
Variable n
MPA AUC
(g  h/mL)
MPA Css
(g/mL)
MP
Clear
(L/h-
very-12-h administration
Day 21 4 11.90 0.99 1.0
(11.8-23.3) (0.98-1.94) (0.69-1
Day 27 0
very-8-h administration
Day 21 15 20.99 2.62 0.7
(3.5-36.3) (0.44-4.54) (0.41-4
Day 27 11 21.14 2.64 0.6
(14.17-42.3) (1.77-5.28) (0.33-1
very-6-h administration
Day 21 5 14.52 2.42 1.0
Day 21 5 (6.62-21.8) (1.10-3.63) (0.73-2
Day 27 6 16.97 2.83 0.9
(6.57-24.1) (1.09-4.02) (0.59-2E indicates not evaluable.
B&MTo 27. The MPA clearance did not consistently increase
r decrease, which is consistent with the minimal change
n the median MPA Css and AUC over time. The me-
ian half-life of MPA was 1.27 hours (range, 0.62-3.62
ours). The median oral bioavailability was 63%, with a
ange of 13% to 161%. The median levels of MPA for
he scheduling intervals and total daily doses over time
n days 0, 7, 14, 21, and 27 are reported in Tables 2 and
. Cmax levels of MPA were comparable for all schedul-
ng intervals. There was no correlation between Ctrough
nd Css (R2 3% for any dosing interval). No second
eaks from the enterohepatic circulation of MPA were
bserved (Figure 1). The unbound fraction was approx-
mately 1% of total MPA at all scheduling intervals and
ays of study after HCT (Table 4).
Cmax
(g/mL) Tmax (h)
Ctrough
(g/mL) t1/2 (h)
7.65 2 0.22 1.25
(6-10.8) (1-2) (0-1.49) (0.84-1.34)
6.35 2 0.17 1.47
(4.4-10.7) (1-2) (0.1-1.21) (1.39-1.59)
12.65 2 0.2 1.27
(4.5-54.1) (1-2.5) (0.04-0.6) (0.75-1.87)
8.42 2 0.13 1.01
(1.11-37.8) (1-3) (0-0.94) (0.64-2.84)
8.31 2 0.29 1.3
(3.19-21.1) (1-2.17) (0.1-1.2) (0.98-2.13)
9.49 2 0.3 1.3
(3.50-24.4) (1-2.08) (0.09-1.44) (0.91-2.04)
5.85 2 0.39 0.81
(3.44-10.8) (2-2) (0.05-1.14) (0.62-1.37)
6.61 1.5 0.64 1.07
(5.1-17.6) (1-2) (0.25-7.06) (0.76-1.36)
11.4 2 0.61 0.87
(5.18-13.6) (1-2.25) (0.19-0.79) (0.66-1.28)
Cmax
(g/mL) Tmax (h)
Ctrough
(g/mL) t1/2 (h)
3.30 1 0.60 NE
(1.6-16.6) (0.92-2) (0.36-1.2) NE
5.23 1.50 1.40 1.91
(1.12-29.3) (0-4.08) (0.05-2.03) (1.18-3.40)
5.47 2 1.37 2.46
(1.64-12.1) (0.95-2.08) (0.22-3.38) (1.36-3.45)
3.76 1 0.69 2.51
(2.53-6.87) (1.0-2.08) (0.41-2.46) (1.43-3.60)
5.03 2 1.16 2.43
(1.62-7.34) (1-4) (0.52-3.93) (1.73-2.56)nce
g)
04)
15)
3)
65)
41)
26)
64)
31)A
ance
kg)
8
.19)
4
.70)
7
.05)
8
.06)
0
.07)499
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5ngraftment
Forty-ﬁve of the 46 patients received peripheral
lood stem cell grafts. The median CD34 cell dose
as 8.0  106/kg (range, 3.6-28.2  106/kg). All
atients at the 3 dose levels of MMF who survived
onger than 14 days after transplantation engrafted.
he median time to neutrophil engraftment for each
roup was 12 days (range, 9-15 days) for group A, 14
ays (range, 11-18 days) for group B, 13 days (range,
0-17 days) for group C, and 15 days (range, 10-20
ays) for group D. Three patients (group A, n  1;
roup B, n 2) died before neutrophil engraftment of
nfection-related events at days 10, 12, and 14. The 1
atient in group D who received marrow engrafted on
ay 17. Platelet engraftment was achieved at a median
f 10 days (range, 7-34 days) after transplantation. No
ffect of dose level on time to engraftment was ob-
erved for either neutrophils or platelets.
dverse Events
MMF was noted to be without obvious adverse
ffects at all dose levels except for 1 patient in group C
ho developed a dose-limiting toxicity (gastrointesti-
igure 1. CSP and MMF for GVHD prophylaxis: MPA pharmacoki
as administered every 12, 8, and 6 hours from days 0 to 27. The ph
ere receiving only the intravenous formulation of MMF (A-C). O
resented in the day 21 pharmacokinetic studies (D). There were lim
ot presented in the ﬁgure.al; grade 4) on day 8 after HCT attributed to the t
00MF. This was the only patient in whom MMF was
iscontinued before day 28 because of toxicity. Later,
his patient developed severe GVHD of the gastroin-
estinal tract, and therefore it was not clear whether
VHD may also have contributed to the early gas-
rointestinal abnormalities. No dose-limiting toxici-
ies from MMF were noted at the dose of 15 mg/kg
very 12 or 8 hours. There was no signiﬁcant change
n diarrhea volume (days 0-21) as the daily MMF dose
as increased (P  .35 ). There was no association of
PA blood levels with diarrhea volume. The grade of
ral mucositis after myeloablative conditioning for the
5 patients added to group D was no different from
hat for a historical control group receiving CSP and
TX for GVHD prophylaxis. In the phase II part of
he study at the MMF dose of 15 mg/kg every 8 hours
group D), there were 5 grade 3 and 2 grade 4 liver
oxicities and 3 grade 3 renal toxicities from days 0 to
00 after HCT. The median concentration of peak
erum bilirubin and peak serum creatinine was 2.2
g/dL (range, 1.1-40.7 mg/dL) and 2.0 mg/dL
range, 1.1- 4.3 mg/dL), respectively. None of the
enal or liver toxicities were attributable to MMF, and
or days 0, 7, 14, 21, and 27 after allogeneic HCT. MMF (15 mg/kg)
okinetic studies were completed on days 0, 7, and 14 while patients
data from patients who received the oral formulation of MMF are
ata on day 27 pharmacokinetic studies, and therefore these data arenetics f
armac
nly the
ited dhey were generally consistent with the expected tox-
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Bcities from the myeloablative conditioning regimen
r nephrotoxic drugs used after HCT. Four (57%) of
, 7 (46%) of 15, and 3 (50%) of 6 CMV-seropositive
ecipients at the 30, 45, and 60 mg/kg total daily dose
f MMF, respectively, had CMV reactivation. No
eronegative patients developed a CMV infection re-
ardless of the CMV serostatus of the donor. Three
atients at the 45 mg/kg and 1 at the 60 mg/kg dose of
MF who had reactivation also developed CMV dis-
ase. The incidence of CMV reactivation and infec-
ions was comparable to that in previous reports of
nfectious complications after HCT [26]. Except for
he 1 patient in group C with dose-limiting toxicity,
ll patients who survived 4 weeks after HCT com-
leted a full course of MMF. Four patients died before
ay 27, and no adverse effects were attributed to
MF in these patients.
able 4. Unbound MPA Pharmacokinetics
Variable n
Administration
Route
Unboun
very-12-h administration
Day 0 9 IV 0
(0.5
Day 7 9 IV 0
(0.6
Day 14 9 IV 0
(0.7
very-8-h administration
Day 0 16 IV 0
(0.4
Day 7 17 IV 0
(0.3
Day 14 15 IV 1
(0.6
Day 21 9 PO 0
(0.8
very-6-h administration
Day 0 7 IV 0
(0.5
Day 7 6 IV 1
(0.6
Day 14 5 IV 1
(0.7
V indicates intravenous; PO, oral.
able 5. Acute GVHD: Grade and Organ Involvement
MMF Group
Acute
Grade II/IV, n (%) Grade II/
hase I only
A (n  10) 5 (50%) 4
B (n  11) 4 (36%) 4
C (n  10) 7 (70%) 4
hase I/II
D (n  26*) 16 (62%) 12
roup A indicates 15 mg/kg every 12 hours; group B, 15 mg/kg ev
additional patients), 15 mg/kg every 8 hours; S, GVHD in skin; G, G
B&MTcute and Chronic GVHD
The incidence of grade II to IV acute GVHD in
roups A, B, and C was 50% (5/10), 36% (4/11), and
0% (7/10), respectively (Table 5; Figure 2). Because
dose-limiting toxicity had occurred in group C with
o improvement in the incidence of acute GVHD and
ecause MPA concentrations were obtained in the
lasma consistent with the therapeutic range for solid-
rgan transplantation, the dose level for group B (15
g/kg every 8 hours) was selected for the phase II part
f the study (group D). In group D, the incidence of
rade II to IV and grade III to IV acute GVHD was
2% (16/26) and 16% (4/26), respectively. Gastroin-
estinal GVHD occurred in all 16 patients diagnosed
ith GVHD in group D. First-line systemic treatment
f acute GVHD was corticosteroids in all patients.
tion Unbound MPA AUC
(gh/mL)
Unbound MPA Css
(g/mL)
0.21 0.02
(0.07-0.97) (0.01-0.08)
0.13 0.01
(0.10-0.27) (0.01-0.02)
0.42 0.04
(0.11-0.88) (0.01-0.07)
0.15 0.02
(0.04-0.51) (0.01-0.06)
0.22 0.03
(0.10-2.13) (0.01-0.27)
0.27 0.03
(0.13-1.41) (0.02-0.18)
0.19 0.02
(0.11-0.60) (0.01-0.08)
0.18 0.03
(0.09-0.26) (0.02-0.04)
0.26 0.04
(0.10-0.43) (0.02-0.03)
0.28 0.05
(0.10-1.79) (0.02-0.3)
Secondary Systemic
Therapy for GVHD
(n)) Organ System (n)
S-4, G-3, L-1 0
S-3, G-4, L-0 0
S-5, G-7, L-1 1
S-13, G-16, L-2 3
ours; group C, 15 mg/kg every 6 hours; Group D (group B  15d Frac
(%)
.8
-6.19)
.86
8-4.84)
.96
4-2.49)
.82
7-2.02)
.99
2-4.49)
.24
5-2.95)
.92
4-2.84)
.88
4-1.36)
.05
6-3.29)
.00
1-5.09)GVHD
III-IV (n
/1
/0
/3
/4
ery 8 h
VHD in gastrointestinal tract; L, GVHD in liver.
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5ne patient in group C and 3 patients in group D had
teroid-refractory GVHD and required secondary
ystemic therapy with additional immunosuppressive
gents. In a matched concurrent cohort of 36 patients
ith advanced hematologic malignancies who had re-
eived CSP and MTX after myeloablative condition-
ng and peripheral blood stem cell transplantation, the
ncidence of grade II to IV and grade III to IV acute
VHD was 70% and 17%, respectively.
No decrease in the occurrence of GVHD was
ssociated with the increasing dose of MMF. More-
ver, there was no decrease in the risk of developing
VHD with higher MPA plasma concentrations. A
ime-dependent analysis of Css above the median for
otal MPA (2.7 g/mL), using the last available value
efore the onset of grade II to IV GVHD, yielded a
azard ratio of 1.5 (range, 0.7-3.2; P  .30). A time-
ependent analysis of Css above the median for un-
ound MPA (0.02 g/mL) and grade II to IV GVHD
ielded a hazard ratio of 1.4 (range, 0.6-3.1; P  .40).
lthough follow-up was limited, the incidence of
hronic GVHD requiring therapy in 29 evaluable pa-
ients who survived 75 days without relapse was 72%
21/29).
elapse and Survival
In the phase I of the study, relapses occurred in
0% (3/10) of patients in group A, 27% (3/11) of
atients in group B, and 50% (5/10) of patients in
roup C. In phase II, there were 6 relapses in the
dditional 15 patients, for an overall incidence of 35%
9/26) in group D. Relapses occurred at a median of
65 days (range, 30-630 days) after transplantation.
ay 100 mortality was 40% (4/10) in group A, 36%
4/11) in group B, and 40% (4/10) in group C. In the
dditional 15 patients for group D, there were 2
eaths, for a total day 100 mortality in group D of
3% (6/26). Overall and event-free survival after
igure 2. Incidence of grade II to IV acute GVHD with 3 different
otal daily doses of MMF. The incidence of GVHD was 40%, 62%,
nd 70% at the MMF daily doses of 30, 45, and 60 mg/kg, respec-
ively.ransplantation were comparable for all doses of
O
02MF. The high mortality was consistent with the
iagnosis and stage of the patient at presentation for
ransplantation. Mortality resulted mostly from non-
elapse complications (Table 6).
ISCUSSION
The combination of CSP and MMF has been
hown to be effective GVHD prophylaxis after my-
loablative conditioning in a dog model of allogeneic
CT and is widely used for preventing rejection of
ematopoietic cell grafts and GVHD after nonmy-
loablative conditioning with low-dose total body ir-
adiation (200 cGy) [9,10]. A few phase II clinical
tudies have been conducted on the combination of
MF with CSP for GVHD prevention after myeloa-
lative conditioning and HCT [13,27,28]. In a small
tudy, 14 patients were treated with CSP combined
ith oral MMF 1 g twice daily administered from days
to 14 [13]. No toxicities attributable to MMF were
bserved, and the median number of days to 500
eutrophils per microliter was 11 days (range, 9-20
ays). Acute GVHD was observed in 7 patients (grade
I, n  6; grade III, n  1). This was comparable to
he incidence of acute GVHD in a control group that
eceived the combination of CSP and MTX for
VHD prophylaxis. The mean trough plasma con-
entration of MPA was 0.28 g/mL, which was below
he trough levels measured after solid-organ trans-
lantation, and no data were given on AUC. In a
ollow-up study of 15 patients by the same group, the
V formulation was administered at escalating daily
oses of MMF ranging from 25 to 34 mg/kg for 21
ays after transplantation [27]. Grade II to III acute
VHD developed in 40%, and no signiﬁcant toxici-
ies were noted. The median trough level of plasma
PA was 0.15 g/mL, and the mean ﬁrst-day
UC0-12 at the dose of 34 mg/kg/d MMF was 25.7 g
h/mL. The development of acute GVHD after
CT in studies of the combination of CSP and MMF
eemed no better than the expected historical experi-
nce; however, MPA levels were lower than the re-
orted experience in healthy volunteers and after sol-
d-organ transplantation. Therefore, this study was
able 6. Causes of Death (n  31)
Variable n
elapse 14
VHD 4
egimen-related toxicity 1
nterstitial-pneumonitis 1
nfection
Viral 1
Bacterial 6
Fungal 2
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Besigned in 2 phases in which the ﬁrst phase was a
ose escalation of MMF. The short half-life and low
rough levels of MPA observed after allogeneic HCT
ay reﬂect a low prevalence of the second delayed
eak from a reduced enterohepatic circulation. This
ay occur after myeloablative conditioning and allo-
eneic HCT because of the mucosal damage due to
adiation or high-dose chemotherapy and/or the re-
uction in bacterial ﬂora in the gastrointestinal tract
rom broad-spectrum antibiotic use. Moreover, when
SP is used in combination with MMF, the excretion
f glucuronidated MPA into the bile may be reduced,
hus causing a further reduction in the enterohepatic
irculation of MPA [29]. In this study, the daily MMF
ose was escalated by shortening the administration
nterval from every 12 hours to every 6 hours. Because
he inhibition of IMPDH is reversible so that the
ctivity of the enzyme recovers as MPA levels de-
rease, shortening the dosing interval was considered
o be a potentially more effective strategy for main-
aining a consistent level of immunosuppression. The
ighest total daily MMF dose evaluated was 60 mg/
g—approximately twice what has been previously
eported in other studies of GVHD prophylaxis [27].
t the daily MMF doses of 15 mg/kg every 8 hours
group B) or 6 hours (group C), the median Css was
.8 and 3.1 g/mL, respectively. These plasma levels
f MPA were consistent with the therapeutic window
escribed from the solid-organ transplantation expe-
ience [30-36].
Over days 1 to 27, MPA clearance and, thus, Css
id not change, potentially because of the large inter-
ose variability. The median bioavailability of MMF
as 63%, which is lower than the 94.1% bioavailabil-
ty reported in healthy volunteers [37]. The dose of
MF may need to be increased when converting from
V to oral administration, although conﬁrmatory data
re needed. Similar to the solid-organ transplant set-
ing, we observed that the trough concentration was
ot consistently related to the MPA Css.
The use of MMF has been associated with adverse
vents in the gastrointestinal tract and the hematopoi-
tic system and with an increased risk of infections
fter solid-organ transplantation. The administration
f high doses of MMF after myeloablative condition-
ng could have potentially exacerbated toxicity to the
astrointestinal tract. However, the most signiﬁcant
dverse event noted in this study was a grade 4 toxicity
f the gastrointestinal tract in 1 patient who was re-
eiving MMF 15 mg/kg every 6 hours. Except for this
atient, no evidence of signiﬁcant gastrointestinal tox-
city was noted at this MMF dose on the basis of the
evel of recorded diarrhea, and all patients but 1 in the
roup completed the scheduled 28-day course of
MF. Although the clinical impression was that oral
ucositis was decreased in patients who had received
MF rather than MTX as GVHD prophylaxis, this l
B&MTas not conﬁrmed in the subset analysis. There was no
vidence that any of the MMF doses delayed hema-
opoietic recovery. The median time to engraftment
n all groups was less than 16 days, which was the
edian time to neutrophil engraftment after trans-
lantation with peripheral blood stem cells and
VHD prophylaxis with CSP and MTX [15]. The
evelopment of infections in all groups was compara-
le and not greater than what would be expected
istorically. The dosing interval for MMF of every 8
ours was selected because an MPA Css in the rec-
mmended therapeutic window for solid-organ trans-
lantation had been achieved, and at the highest daily
ose evaluated, a signiﬁcant gastrointestinal adverse
vent had been observed. Moreover, there was a par-
doxical increase in the incidence of acute GVHD
ssociated with the increased dose of MMF in group
. There was also a concern that the potential gastro-
ntestinal adverse events associated with a higher dose
f MMF could complicate the diagnosis of gastroin-
estinal GVHD [6].
The incidence of grade II to IV acute GVHD has
ncreased since the early 1990s as a result of better
etection of stage 1 gastrointestinal GVHD. In early
tudies of pharmacologic prophylaxis for GVHD, the
ombination of CSP and short MTX was associated
ith an incidence of grade II to IV acute GVHD of
0% to 40% after transplantation of marrow from
LA-matched donors [1,2,38]. In a multicenter phase
II study of CSP/MTX versus tacrolimus/MTX,
hich included 329 patients after HLA-matched sib-
ing transplantation, the incidence of grade II to IV
cute GVHD was 44.4% in the CSP group [3]. How-
ver, in this study, a matched concurrent cohort of 36
atients who had received CSP and MTX after my-
loablative conditioning had an incidence of grade II
o IV acute GVHD of 70%. We also performed a
etrospective analysis of 30 patients with advanced
ematologic malignancies from a previously reported
tudy that compared marrow with mobilized periph-
ral blood stem cells as the source of the graft [15]. In
hese 30 patients, who underwent transplantation with
eripheral blood stem cells and received CSP/MTX
or GVHD prophylaxis, 77% developed grade II to IV
cute GVHD (B.S., personal communication). These
bservations are consistent with a recent large retro-
pective analysis at the Fred Hutchinson Cancer Re-
earch Center in which the incidence of grade II to IV
cute GVHD after HCT from an HLA-identical sib-
ing was as high as 60% to 70%. This increase in acute
VHD has predominantly resulted from an increased
ncidence of stage 1 gastrointestinal involvement from
0% to 20% before 1992 to 50% to 60% since 1992
ecause of increased clinical awareness and better de-
ection [17]. In previous reports, the efﬁcacy of MMF
n combination with CSP after HCT may have been
ess than optimal secondary to the shorter half-life and
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5ow trough levels of MPA compared with that after
olid-organ transplantation. However, we were unable
o demonstrate that the escalated daily dose of MMF
ith a shortened dosing interval and a therapeutic Css
or MPA was associated with a reduced risk for the
evelopment of acute GVHD. Longer administration
f MMF beyond day 27 may be a more effective
trategy for reducing the incidence of grade II to IV
cute GVHD, because 7 of 16 patients in group D
tarted primary treatment for acute GVHD after stop-
ing MMF. Tacrolimus may be more effective than
SP in combination with MMF for preventing
VHD because earlier studies have shown that ta-
rolimus is more effective than CSP when used in
ombination with MTX [3,4]. Because tacrolimus
oes not reduce MPA levels when used in combina-
ion with MMF, dosing strategies different from those
escribed in this study may be required for MMF.
There was 1 grade 4 gastrointestinal adverse event
t the highest MMF dose level evaluated, but MMF
as otherwise well tolerated at all dose levels as part of
GVHD prophylaxis regimen after myeloablative
onditioning and HCT. MPA levels (Css) that were
ffective for the prevention of kidney graft rejection
ere achieved with an MMF dose of 15 mg/kg ad-
inistered every 8 hours. The incidence of acute
VHD was comparable but not reduced from what
ould be expected with the standard GVHD prophy-
axis of CSP and MTX. On the basis of the outcome
ata from this study, it is unlikely that a phase III study
f the combination of CSP and MMF would show a
igniﬁcant decrease in the incidence of acute GVHD
ompared with CSP and MTX. MMF in combination
ith CSP could be considered in cases in which MTX
s contraindicated, such as in the presence of renal
ailure or with signiﬁcant collections of extravascular
uid.
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